![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Through the divestment, the company has acquired the rights and will concentrate on commercializing Loxacin (loxapine succinate) for treating psychotic disorders and personality disorders.
Lead Product(s): Loxapine Succinate
Therapeutic Area: Psychiatry/Psychology Product Name: Loxapac
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CNX Therapeutics
Deal Size: $61.3 million Upfront Cash: Undisclosed
Deal Type: Divestment April 02, 2024